STOCK TITAN

Director at Adicet Bio (ACET) receives 4,200 stock options award

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Adicet Bio, Inc. director Lloyd Klickstein received a grant of stock options covering 4,200 shares of common stock. The options have an exercise price of $8.10 per share and expire on June 20, 2036. They vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, subject to his continued service on the board. This is a routine equity compensation award and does not involve any open-market buying or selling of shares.

Positive

  • None.

Negative

  • None.

Insights

Routine director stock option grant with standard vesting terms.

Director Lloyd Klickstein was granted options on 4,200 Adicet Bio shares at an exercise price of $8.10, expiring on June 20, 2036. The filing classifies this as a grant or award, not an open-market transaction.

The options vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, contingent on continued board service. Such awards are a common way to align director incentives with shareholders and are typically viewed as routine rather than thesis-changing events.

Insider Klickstein Lloyd
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 4,200 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 4,200 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 4,200 options Stock Option (Right to Buy) granted to director
Exercise price $8.10 per share Conversion or exercise price of stock options
Underlying shares 4,200 shares Common stock underlying the options
Total options after grant 4,200 options Total derivative shares following transaction
Expiration date June 20, 2036 Option expiration date
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 8.1000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-20T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
annual meeting of stockholders financial
"the date of the next annual meeting of stockholders following the grant date"
board of directors financial
"subject to the Reporting Person's continued service on the Issuer's board of directors"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Klickstein Lloyd

(Last)(First)(Middle)
C/O ADICET BIO, INC.
131 DARTMOUTH STREET, FLOOR 3

(Street)
BOSTON MASSACHUSETTS 02116

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Adicet Bio, Inc. [ ACET ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/21/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$8.106/21/2026A4,200 (1)06/20/2036Common Stock4,200$04,200D
Explanation of Responses:
1. These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.
/s/ Nick Harvey, Attorney-in-Fact06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Adicet Bio (ACET) disclose for Lloyd Klickstein?

Adicet Bio disclosed that director Lloyd Klickstein received a grant of stock options for 4,200 shares of common stock. The options are a compensation award, not an open-market purchase or sale, and increase his potential future equity exposure to the company.

How many Adicet Bio (ACET) stock options were granted to Lloyd Klickstein and at what price?

Lloyd Klickstein was granted options on 4,200 Adicet Bio common shares with an exercise price of $8.10 per share. This means he can choose to buy those shares at $8.10 in the future, any time before the options expire, once they vest.

When do Lloyd Klickstein’s Adicet Bio (ACET) stock options vest?

The options vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders. Vesting is conditioned on Klickstein’s continued service on Adicet Bio’s board, so leaving the board early could affect the vesting outcome.

What is the expiration date of Lloyd Klickstein’s Adicet Bio (ACET) stock options?

The granted stock options expire on June 20, 2036, providing roughly a decade-long exercise window after vesting. If the options are not exercised by that expiration date, they will lapse and no longer give Klickstein the right to purchase Adicet Bio shares.

Did Lloyd Klickstein buy or sell Adicet Bio (ACET) shares in the market?

The filing shows a grant of stock options as compensation, not a market trade. There were no reported open-market purchases or sales of Adicet Bio common shares by Lloyd Klickstein in this transaction; it purely reflects an equity award from the company.

How many Adicet Bio (ACET) options does Lloyd Klickstein hold after this grant?

After this transaction, Lloyd Klickstein holds stock options representing 4,200 shares of Adicet Bio common stock. The filing does not list additional derivative positions, so this grant establishes his reported option holdings at that level in this specific disclosure.